Investing
Insider Buying Soars as Q1 Earnings Wind Up: Tempur Sealy, Apollo Global, Revlon, Kite Pharma and More
Published:
Last Updated:
We said it for most of April, but this past week really proved the point. Windows for corporate executives to sell and buy shares close during earnings reporting season, and when they started to open last week, the buyers stormed back into the market in full force. Buyers appeared to swamp the sellers, and if last week was any indication, it’s a good bet that we will see continued strength through the rest of the month.
We cover insider buying each week at 24/7 Wall St., and we like to remind readers that while insider buying is usually a very positive sign, it is not in of itself a reason to run out and buy a stock. Sometimes insiders and 10% owners have stock purchase plans set up at intervals to add to their holdings. That aside, it still remains an overall positive indicator.
Here are some of the companies that reported notable insider buying last week.
Tempur Sealy International Inc. (NYSE: TPX) had a 10% owner of the company making a huge purchase this past week. H Partners bought a massive 610,000 shares of the stock at prices that ranged from $48.09 to $48.41. The total for the trade was posted at a whopping $30 million. The shares closed on Friday at $48.66. The Wall Street consensus price target is $50.67, and the 52-week trading range is $39.52 to $87.37.
Apollo Global Management LLC (NYSE: APO) had a huge hedge fund once again buying shares last week. Tiger Global Management purchased 431,500 shares of the private equity giant at prices that ranged from $26.48 to $27.31. The total for the purchase was reported at $12 million. Earlier in the week, the company had bought 298,200 shares at prices from $26.04 to $26.49. This trade cost $8 million. The stock close last Friday at $26.98, in a 52-week range of $14.25 to $27.78. The consensus price target is $30.00.
Revlon Inc. (NYSE: REV) had a director who is a 10% owner purchasing share last week. That board member bought a total of 950,000 shares of the personal care products giant at prices that ranged from $20.38 to $20.47. The total for the purchase was posted at $19 million. However, the shares closed Friday at $19.90. The 52-week range is $18.30 to $37.96, and the consensus price target is set at a surprising $42.00.
MINDBODY Inc. (NASDAQ: MB) had 10% institutional owner adding to a position last week. Luxor Capital picked up an additional 469,973 shares of the cloud-based wellness business management software company at $25.46 per share. The total for the purchase was set at $12 million. The shares closed last Friday at $26.55. The consensus price target is $30.75, and the 52-week range is $12.99 to $29.75.
Kite Pharma Inc. (NASDAQ: KITE) saw its CEO, Dr. Arie Belldegrun, and a director at the company buying shares last week. The pair purchased a total of 67,000 shares at prices between $68.57 and $68.94 apiece. The total for the purchases was posted at $5 million. The shares closed last Friday at $75.43, so the timing looks outstanding. The 52-week range is $39.82 to $88.58. The consensus price objective is $86.46.
These companies also reported insider buying last week: Opko Health Inc. (NASDAQ: OPK), Plains GP Holdings L.P. (NYSE: PAGP), Regis Corp. (NYSE: RGS), Tallgrass Energy Partners L.P. (NYSE: TEP) and Unifi Inc. (NYSE: UFI).
What a difference a couple of weeks can make in the world of insider activity, and given the strength this week, any pullback in the market may bring a torrent of buying as insiders add to their holdings.
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.